CN119212996A - Pi3k抑制剂的结晶形式和盐及其制备方法和使用方法 - Google Patents

Pi3k抑制剂的结晶形式和盐及其制备方法和使用方法 Download PDF

Info

Publication number
CN119212996A
CN119212996A CN202380040223.8A CN202380040223A CN119212996A CN 119212996 A CN119212996 A CN 119212996A CN 202380040223 A CN202380040223 A CN 202380040223A CN 119212996 A CN119212996 A CN 119212996A
Authority
CN
China
Prior art keywords
crystalline form
peaks
exhibits
compound
xrpd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380040223.8A
Other languages
English (en)
Chinese (zh)
Inventor
N·S·达万
J·A·布莱尔
R·B·佩尔尼
J·L·兰道尔
X·王
M·李
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tottes Pharmaceuticals
Original Assignee
Tottes Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tottes Pharmaceuticals filed Critical Tottes Pharmaceuticals
Publication of CN119212996A publication Critical patent/CN119212996A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265—Citric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202380040223.8A 2022-03-24 2023-03-24 Pi3k抑制剂的结晶形式和盐及其制备方法和使用方法 Pending CN119212996A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2022082752 2022-03-24
CNPCT/CN2022/082752 2022-03-24
PCT/CN2023/083760 WO2023179771A1 (en) 2022-03-24 2023-03-24 Crystalline forms and salts of a pi3k inhibitor and methods of making and methods of use thereof

Publications (1)

Publication Number Publication Date
CN119212996A true CN119212996A (zh) 2024-12-27

Family

ID=86286092

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380040223.8A Pending CN119212996A (zh) 2022-03-24 2023-03-24 Pi3k抑制剂的结晶形式和盐及其制备方法和使用方法

Country Status (8)

Country Link
US (1) US20250197408A1 (enExample)
EP (1) EP4499642A1 (enExample)
JP (1) JP2025509950A (enExample)
KR (1) KR20250044815A (enExample)
CN (1) CN119212996A (enExample)
AU (1) AU2023240100A1 (enExample)
CA (1) CA3246202A1 (enExample)
WO (1) WO2023179771A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220079866A (ko) 2019-09-19 2022-06-14 토투스 메디신스 아이엔씨. 치료 접합체

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220079866A (ko) 2019-09-19 2022-06-14 토투스 메디신스 아이엔씨. 치료 접합체

Also Published As

Publication number Publication date
KR20250044815A (ko) 2025-04-01
JP2025509950A (ja) 2025-04-11
AU2023240100A1 (en) 2024-10-03
CA3246202A1 (en) 2023-09-28
EP4499642A1 (en) 2025-02-05
US20250197408A1 (en) 2025-06-19
WO2023179771A1 (en) 2023-09-28

Similar Documents

Publication Publication Date Title
ES2872553T3 (es) Inhibidores de lisil oxidasa tipo-2 y usos de los mismos
JP6317320B2 (ja) 上皮成長因子受容体キナーゼ阻害剤の塩
JP2022106967A (ja) 癌の治療のためのｅｒｂｂチロシンキナーゼ阻害剤としてのベンゾイミダゾール誘導体
JP2023500395A (ja) Ｐｄ－１／ｐｄ－ｌ１阻害剤の塩及び結晶形態
CN107428765B (zh) 用作irak抑制剂的哒嗪酮类大环化合物及其用途
BR112014022789B1 (pt) Formas sólidas de um inibidor de quinase de receptor do fator de crescimento epidérmico, composição farmacêutica e usos do mesmo
BRPI0806811A2 (pt) derivados de purina
CN112055714B (zh) 二甲基氧膦类化合物
JP7775186B2 (ja) アクチビン受容体様キナーゼ阻害剤の塩及び結晶形態
CN110577543B (zh) 一种二氢咪唑并吡嗪酮化合物及包含该化合物的组合物及其用途
WO2023174400A1 (zh) 一种取代的氨基六元氮杂环类化合物的盐及其晶型、制备方法和应用
WO2023179771A1 (en) Crystalline forms and salts of a pi3k inhibitor and methods of making and methods of use thereof
KR102847760B1 (ko) 디아미노피리미딘 화합물 또는 이의 수화물의 고체 형태, 이의 제조 방법 및 이의 용도
WO2024061172A1 (zh) 一种脯氨酰羟化酶抑制剂及其用途
US20250213581A1 (en) Combination therapy of a pi3k inhibitor and kras inhibitor and methods of use thereof
US12559472B2 (en) Salts of a compound and the crystalline forms thereof
WO2024086664A2 (en) Covalent inhibitors of wild-type and mutant pi3k and method of uses thereof
CN110256408B (zh) 一种二芳基吡唑化合物及包含该化合物的组合物及其用途
KR102967623B1 (ko) 액티빈 수용체 유사 키나아제 저해제의 염 및 결정 형태
CN108299419B (zh) 一种新型egfr激酶抑制剂的几种新晶型及其制备方法
CN115490640B (zh) 取代的苯并咪唑类化合物及包含该化合物的组合物及其用途
HK40072576B (zh) 用作激酶抑制剂的化合物及其应用
WO2026017041A1 (zh) 一种吡唑并喹唑啉类化合物及其盐型和晶型
CN121735914A (zh) 一种用于进行癌症免疫治疗的parp7抑制剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination